Soligenix's HyBryte Shows Superior Efficacy and Safety Over Valchlor in Cutaneous T-Cell Lymphoma Treatment

Soligenix Inc. announced the publication of positive results from its comparability study evaluating HyBryte versus Valchlor for the treatment of cutaneous T-cell lymphoma in Oncology and Therapy, highlighting favorable efficacy and safety outcomes. After 12 weeks, 60% of HyBryte-treated patients achieved treatment success compared to 20% for Valchlor, with greater average improvement and no treatment-related adverse events reported for HyBryte, while Valchlor patients experienced multiple adverse reactions. These findings support HyBryte's potential as a well-tolerated therapy for early-stage CTCL, a rare cancer affecting the skin's immune cells.

The study's results are particularly significant given the limited treatment options available for cutaneous T-cell lymphoma patients and the often challenging side effect profiles of existing therapies. The complete absence of treatment-related adverse events with HyBryte represents a substantial advancement in patient care, potentially allowing for better treatment adherence and improved quality of life. The three-fold higher treatment success rate compared to Valchlor suggests HyBryte could become a preferred first-line treatment option if these results are confirmed in larger studies and through regulatory review.

Soligenix is developing HyBryte as a novel photodynamic therapy utilizing safe visible light, representing a different mechanism of action from existing treatments. The company's Specialized BioTherapeutics business segment is moving toward potential commercialization of HyBryte following successful completion of the second Phase 3 study. Regulatory approvals will be sought to support potential commercialization worldwide, with development programs also including expansion of synthetic hypericin into psoriasis treatment. Additional information about the company's research can be found at https://ibn.fm/SNGX.

The implications of these study results extend beyond immediate treatment improvements for CTCL patients. The favorable safety profile demonstrated by HyBryte could reduce healthcare costs associated with managing treatment side effects and complications. Furthermore, the success of this photodynamic therapy approach may encourage research into similar mechanisms for other dermatological conditions and cancers. As Soligenix advances toward regulatory submissions, these published results provide important validation of HyBryte's clinical potential and support its development as a meaningful advancement in the treatment of rare diseases with unmet medical needs.